ArticleAmerican journal of translational research2026
Low-temperature plasma radiofrequency ablation is effectively treats early glottic carcinoma.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the treatment efficacy of low-temperature plasma radiofrequency ablation (LTP-RFA) in patients with early glottic carcinoma (EGC).
methodsA total of 80 EGC patients were retrospectively selected and divided into a control group (standard laryngofissure) and a research group (LTP-RFA) based on their treatment methods. Surgery-related indicators, visual analogue scale (VAS) and mucosal recovery scores, efficacy, serum indices, voice acoustics (amplitude perturbation, fundamental frequency perturbation, harmonic-to-noise ratio), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTCQLO-C30) scores, complications, and postoperative recurrence were compared between the two groups.
resultsCompared to the control group, patients in the LTP-RFA group demonstrated markedly shorter surgery time, less intraoperative blood loss, and reduced length of hospital stay. In addition, postoperative VAS score, mucosal recovery score, and the total complication rate were all lower in the research group, with a higher overall effective rate. The research group also exhibited greater reductions in post-treatment serum biomarker levels (e.g., matrix metalloproteinase-9 (MMP-9), nitric oxide (NO), or vascular endothelial growth factor (VEGF)), better improvements in acoustic parameters (e.g., amplitude perturbation, fundamental frequency perturbation, and harmonic-to-noise ratio) than the control group, along with higher total EORTCQLO-C30 scores. The recurrence rate was equivalent in the two groups.
conclusionLTP-RFA is an effective treatment for EGC, offering advantages in improving therapeutic efficacy, voice acoustics, as well as reducing postoperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.